The text starts here.

News Release

February 2, 2005

Transfer of Marketing Rights of ACE Inhibitor Inhibace(R) from Eisai to Chugai

Chugai Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Osamu Nagayama) and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) have agreed to transfer marketing rights of Inhibace(R) (generic name: cilazapril) from Eisai to Chugai based on the termination of agreement on March 31, 2005. As a result, Chugai will become the sole marketer of Inhibace(R) in Japan from April 1, 2005.

Inhibace(R) is an antihypertensive agent synthesized by Roche, and categorized as an ACE (angiotensin converting enzyme) inhibitor. It has a high affinity to ACE and shows ACE inhibitory action for a long time. These characteristics allow the compound to be a persistent ACE inhibitor that can be administered orally once daily and control blood pressure well.
Nippon Roche K.K. (currently Chugai Pharmaceutical) and Eisai started to market Inhibace(R) under a single brand through two-channels in Japan from November 1990. The marketing was then integrated to Eisai from January 1995.

Contacts :
Chugai Pharmaceutical Co., Ltd.Corporate Communications Department

TEL : 03-3273-0881
Eisai Co., Ltd.Corporate Communications Department

TEL : 03-3817-5120

[Reference Data]

[ Summary of Inhibace(R) ]
Product NameInhibace Tablet 0.25   Inhibace Tablet 0.5   Inhibace Tablet 1
Generic NameCilazapril
Constitution Inhibace Tablet 0.25 White film-coated tablet including cilazapril 0.261mg (0.25mg as anhydride) in one tablet
Inhibace Tablet 0.5White film-coated tablet including cilazapril 0.522mg (0.5mg as anhydride) in one tablet
Inhibace Tablet 1White film-coated tablet including cilazapril 1.043mg (1mg as anhydride) in one tablet
Indication and UsageHypertension
Dosage and AdministrationThe usual initial dosage for adults is 0.5mg as cilazapril anhydride, given orally once daily. The dosage is then gradually increased with a maximum dose of 2mg once daily. Patients in critical condition or those accompanied by renal disorder are started at 0.25mg as cilazapril anhydride once daily.Dosage should be adjusted depending on each patient's age and symptoms.
Drug Price Inhibace Tablet 0.25JPY 29.70
Inhibace Tablet 0.5JPY 49.60
Inhibace Tablet 1JPY 77.20
Launch DateNovember 1990
ManufacturerChugai Pharmaceutical Co., Ltd.
Eisai Co., Ltd.